首页> 外文期刊>The Journal of Veterinary Medical Science >Immunological and Genetic Characterization of Feline Caliciviruses Used in the Development of a New Trivalent Inactivated Vaccine in Japan
【24h】

Immunological and Genetic Characterization of Feline Caliciviruses Used in the Development of a New Trivalent Inactivated Vaccine in Japan

机译:在日本开发新型三价灭活疫苗的猫杯状病毒的免疫学和遗传学表征

获取原文
           

摘要

References(35) Cited-By(1) Although vaccination against feline calicivirus (FCV) infection is widespread in Japan, FCV-associated diseases are still a significant problem in cats. Thus, we developed a new trivalent inactivated vaccine, Kyoto Biken Feline-CPR, consisting of three FCV strains; one was the production strain of our previous vaccine, and the others were screened from 60 field isolates obtained between 1998 and 2000 based on cross-neutralization tests. In this report, the three FCV strains used for development of the new vaccine were antigenically and genetically characterized. The three strains were antigenically quite different, as revealed by cross-neutralization tests. Alignment of deduced amino acid sequences of capsid regions A to E revealed that there were marked differences between the strains in both the N- and C ends of region E. Antisera against the three vaccine strains, our new vaccine and 2 commercial vaccines were then evaluated for neutralization with 58 field isolates collected between 2003 and 2006. Rat antisera against the three vaccine strains and a mixture of the 3 strains neutralized 49, 37, 42 and 55 isolates, respectively. Cat antiserum against the new vaccine neutralized 50 (86.2%) isolates, whereas the numbers neutralized by cat antisera against 2 commercial vaccines were 37 (63.8%) and 25 (43.1%). In conclusion, the immunological and genetic properties of the 3 vaccine strains investigated varied widely, and the Kyoto Biken Feline-CPR vaccine may have more potential to meet the antigenic diversity of FCVs spreading throughout Japan.
机译:参考文献(35)(1)尽管在日本已经广泛接种了针对猫杯状病毒(FCV)的疫苗,但与FCV相关的疾病仍是猫的重要问题。因此,我们开发了一种新的三价灭活疫苗,即京都比肯猫科动物CPR,它由三种FCV毒株组成。一种是我们先前疫苗的生产菌株,另一种是根据交叉中和测试从1998年至2000年之间获得的60种野外分离株中筛选出来的。在这份报告中,用于新疫苗开发的三种FCV菌株具有抗原性和遗传学特征。交叉中和试验表明,这三种菌株的抗原性完全不同。衣壳区A到E的推导氨基酸序列的比对表明,在E区N和C端的菌株之间存在显着差异。然后评估了针对三种疫苗株,我们的新疫苗和2种商业疫苗的抗血清可以在2003年至2006年间用58种田间分离株进行中和。针对这三种疫苗株和3种菌株的混合物的大鼠抗血清分别中和了49、37、42和55种分离株。针对新疫苗的猫抗血清中和了50种(86.2%)分离物,而针对2种市售疫苗的猫抗血清中和了37种(63.8%)和25种(43.1%)。总之,所研究的3种疫苗株的免疫学和遗传学特性差异很大,Kyoto Biken猫科动物CPR疫苗可能具有更大的潜力来满足在日本传播的FCV的抗原多样性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号